• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    NEXGEL Appoints Scott Henry, CFA to Board of Directors and Audit Committee

    1/17/23 7:30:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care
    Get the next $NXGL alert in real time by email

    LANGHORNE, Pa., Jan. 17, 2023 /PRNewswire/ -- NEXGEL, Inc. (NASDAQ:NXGL, NXGLW))), ("NEXGEL" or the "Company"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, announced today the appointment of Scott Henry, CFA as a new independent director to the Company's Board of Directors (the "Board"), effective immediately. Mr. Henry will also serve as a member of the Board's Audit Committee.

    "Scott brings a wealth of financial and operational experience to NEXGEL, making him an ideal addition to our Board and Audit Committee," said Adam Levy, Chief Executive Officer of NEXGEL. "Additionally, his vast network within the investment community and his extensive knowledge of the small and microcap company landscape will be invaluable towards supporting our growth initiatives going forward. We are grateful to have Scott as part of our team."

    Scott R. Henry, CFA, is a Managing Director, Senior Research Analyst at ROTH Capital Partners with 20 years of sell-side coverage in the pharmaceutical, biotechnology and medical device sectors. He has previously held positions with firms including Oppenheimer, Thomas Weisel Partners, ABN AMRO and Leerink Swann & Co. Mr. Henry has received numerous awards, including rankings in the Wall Street Journal "Best on the Street" stock picking survey, Forbes/Zacks Investment Research "Best Analysts" for the drugs category and Forbes.com/StarMine rankings for earnings estimate accuracy. His investment views have been cited in the Wall Street Journal and the New York Times, and he has made frequent appearances on CNBC, CBS MarketWatch and Bloomberg. Mr. Henry attended the University of Rhode Island and received an M.B.A. with distinction from Cornell University.

    Mr. Henry commented, "After spending extensive time with Adam and the rest of the senior leadership team, I was excited to join the NEXGEL team as a member of the Board and Audit Committee. NEXGEL presents a unique situation with solid assets, talented people and significant growth potential. Leveraging my experience and industry relationships, I believe that together, we can capitalize on these opportunities."

    About NEXGEL, INC.

    NEXGEL is a leading provider of ultra-gentle, high-water-content hydrogels for healthcare and consumer applications. Based in Langhorne, Pa., the Company has developed and manufactured electron-beam, cross-linked hydrogels for over two decades. Alongside its strategic partners, NEXGEL has formulated more than 200 different combinations to bring natural ingredients to gentle skin patches that can be worn for long periods of time with little to no irritation.

    Forward-Looking Statement

    This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act") (which Sections were adopted as part of the Private Securities Litigation Reform Act of 1995). Statements preceded by, followed by or that otherwise include the words "believe," "anticipate," "confidence," "estimate," "expect," "intend," "plan," "project," "prospects," "outlook," and similar words or expressions, or future or conditional verbs, such as "will," "should," "would," "may," and "could," are generally forward-looking in nature and not historical facts. These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Company's actual results, performance, or achievements to be materially different from any anticipated results, performance, or achievements for many reasons. The Company disclaims any intention to, and undertakes no obligation to, revise any forward-looking statements, whether as a result of new information, a future event, or otherwise, except as required by law. For additional risks and uncertainties that could impact the Company's forward-looking statements, please see the Company's Annual Report on Form 10-K for the year ended December 31, 2021, including but not limited to the discussion under "Risk Factors" therein, which the Company filed with the SEC and which may be viewed at http://www.sec.gov/.

    Investor Contact:

    Valter Pinto

    KCSA Strategic Communications

    212.896.1254

    [email protected] 

    Media Contacts:

    Raquel Cona / Michaela Fawcett

    KCSA Strategic Communications

    212.896.1204 / 978.995.4683

    [email protected] / [email protected]

     

    Cision View original content:https://www.prnewswire.com/news-releases/nexgel-appoints-scott-henry-cfa-to-board-of-directors-and-audit-committee-301722564.html

    SOURCE NEXGEL

    Get the next $NXGL alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $NXGL

    DatePrice TargetRatingAnalyst
    2/25/2022$6.00Buy
    Maxim Group
    More analyst ratings

    $NXGL
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Executive Officer Levy Adam R. bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 1% to 333,196 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:14 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Zeldis Jerome B bought $9,999 worth of shares (3,636 units at $2.75), increasing direct ownership by 4% to 106,664 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:12 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    Director Stein John Nachum gifted 4,000 shares and bought $9,999 worth of shares (3,636 units at $2.75), decreasing direct ownership by 0.08% to 471,456 units (SEC Form 4)

    4 - NEXGEL, INC. (0001468929) (Issuer)

    11/22/24 4:54:08 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on NexGel with a new price target

    Maxim Group initiated coverage of NexGel with a rating of Buy and set a new price target of $6.00

    2/25/22 9:17:01 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    NEXGEL Reports Second Quarter 2025 Financial Results

    Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio

    8/12/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2025 Financial Results Conference CallDate: August 12, 2025Time: 4:30 P.M. ETLive Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (I

    8/6/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

    LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader

    8/5/25 8:00:00 AM ET
    $NXGL
    $SSTK
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    $NXGL
    SEC Filings

    View All

    SEC Form 10-Q filed by NexGel Inc

    10-Q - NEXGEL, INC. (0001468929) (Filer)

    8/12/25 5:01:21 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NexGel Inc filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - NEXGEL, INC. (0001468929) (Filer)

    8/12/25 4:10:58 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NexGel Inc filed SEC Form 8-K: Leadership Update, Other Events, Financial Statements and Exhibits

    8-K - NEXGEL, INC. (0001468929) (Filer)

    8/5/25 4:05:32 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Ciardiello Steven claimed ownership of 21,739 shares (SEC Form 3)

    3 - NEXGEL, INC. (0001468929) (Issuer)

    8/5/25 4:10:16 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Henry Scott Robert

    4 - NEXGEL, INC. (0001468929) (Issuer)

    6/27/25 8:00:09 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    SEC Form 4 filed by Director Zeldis Jerome B

    4 - NEXGEL, INC. (0001468929) (Issuer)

    6/27/25 8:00:07 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Financials

    Live finance-specific insights

    View All

    NEXGEL Reports Second Quarter 2025 Financial Results

    Second quarter 2025 revenue totaled $2.88 million, an increase of 100.3% as compared to $1.44 million for the same period year-over-year Gross Profit for the quarter was 43.6%, compared to 20.3% for the same period in 2024 Company is reiterating revenue guidance for 2025 of $13 million and to achieve positive EBITDA during the year LANGHORNE, Pa., Aug. 12, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of healthcare, beauty, and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its second quarter 2025 financial results for the perio

    8/12/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL to Report Second Quarter 2025 Financial Results on August 12th

    Management will host a conference call at 4:30 P.M. ET on the same day LANGHORNE, Pa., Aug. 06, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced it will report its financial results for the second quarter 2025, after the market close on August 12, 2025. Following the release of its financial results, the Company will host a conference call at 4:30 P.M. ET on the same day. Second Quarter 2025 Financial Results Conference CallDate: August 12, 2025Time: 4:30 P.M. ETLive Call: 1-800-274-8461 (U.S. Toll Free) or 1-203-518-9814 (I

    8/6/25 8:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Reports First Quarter 2025 Financial Results

    First quarter 2025 revenue totaled $2.81 million, an increase of 121%, as compared to $1.27 million for the same period the prior year Gross Profit for the quarter was 42.4%, compared to 12.6% in Q1 2024 and 37.2% in Q4 2024 LANGHORNE, Pa., May 13, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of ultra-gentle, high-water-content hydrogel products for healthcare and consumer applications, today announced its first quarter 2025 financial results for the period ending March 31, 2025. First Quarter 2025 Financial Highlights: Net Revenue was $2.81 million, compared to $1.27 million in Q1 2024 and $3.04 million in Q4 2024.Gross Profit

    5/13/25 4:05:00 PM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    $NXGL
    Leadership Updates

    Live Leadership Updates

    View All

    NEXGEL Appoints Chief Accounting Officer of Shutterstock, Steve Ciardiello, CPA, to its Board of Directors

    LANGHORNE, Pa., Aug. 05, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Steve Ciardiello, CPA, to its Board of Directors. With more than 25 years of experience as a senior finance executive and current Chief Accounting Officer of Shutterstock, Inc. (NYSE:SSTK), Mr. Ciardiello has a proven track record of financial leadership, strategic execution, and corporate governance in high-growth, publicly traded companies. "Steve's extensive experience, financial leader

    8/5/25 8:00:00 AM ET
    $NXGL
    $SSTK
    Medical/Dental Instruments
    Health Care
    EDP Services
    Technology

    NEXGEL Appoints Joseph F. McGuire as Chief Financial Officer

    LANGHORNE, Pa., Jan. 02, 2025 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Joseph F. McGuire as Chief Financial Officer, effective January 1, 2025. Adam E. Drapczuk III, current Chief Financial Officer, will remain with the Company as a consultant. Adam Levy, Chief Executive Officer, stated, "As our business continues to experience high growth, it is imperative we consistently acquire talented and experienced professionals to join our team particularly in operati

    1/2/25 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care

    NEXGEL Appoints Kip Crecca to its Scientific Advisory Board

    LANGHORNE, Pa., Oct. 04, 2024 (GLOBE NEWSWIRE) -- NEXGEL, Inc. ("NEXGEL" or the "Company") (NASDAQ: "NXGL"), a leading provider of medical and over-the-counter (OTC) products including ultra-gentle, high-water-content hydrogels for healthcare and consumer applications, today announced the appointment of Kip Crecca to its Scientific Advisory Board. "We are thrilled to appoint Kip to our Scientific Advisory Board. He adds to our team a wealth of knowledge and experience as a top medical device sales professional," said Adam Levy, NEXGEL's CEO. "Mr. Crecca will be invaluable to the Company as we advance our medical device and healthcare programs. He is an important addition to our group of e

    10/4/24 9:00:00 AM ET
    $NXGL
    Medical/Dental Instruments
    Health Care